+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Gastrointestinal stromal tumor: recent advances in pathology and genetics



Gastrointestinal stromal tumor: recent advances in pathology and genetics



Pathology International 65(1): 9-18



The discovery of KIT gene mutation in gastrointestinal stromal tumor (GIST) has provided a paradigm shift in the classification, diagnosis and molecular-targeted therapy of gastrointestinal mesenchymal tumors. There is growing evidence of phenotype-genotype (KIT, platelet-derived growth factor receptor-alpha, succinate dehydrogenase or other driver gene mutation) and genotype-therapeutic (sensitivity to imatinib) correlations in GIST. Risk stratification based on mitotic counts, tumor size and rupture is useful for the prognostication and management of patients with GIST. Blood vessel invasion is a strong indicator of liver metastasis in GIST. In addition, novel biomarkers such as cell-cycle regulators, microRNAs and their targets have been discovered by using high throughput molecular analyses. In contrast, leiomyosarcoma of the gastrointestinal tract has become a very rare entity in the 'KIT' era, and its molecular pathogenetic mechanism is unclear. Recent studies have revealed a wide spectrum of cytological atypia, mitotic counts and biological behavior of gastrointestinal smooth muscle tumors, suggesting the necessity of establishing the criteria for malignancy. Collectively, both classical histopathological procedures and modern molecular investigations are indispensable for the evolution of diagnosis and treatment of GIST and mimics.

(PDF emailed within 0-6 h: $19.90)

Accession: 053355265

Download citation: RISBibTeXText

PMID: 25414046

DOI: 10.1111/pin.12230


Related references

Recent advances in managing gastrointestinal stromal tumor. F1000research 6: 1689, 2017

Dedifferentiated gastrointestinal stromal tumor: Recent advances. Annals of Diagnostic Pathology 2019, 2019

Recent advances and novel agents for gastrointestinal stromal tumor (GIST). Journal of Hematology & Oncology 5: 21-21, 2012

Recent advances and novel agents for gastrointestinal stromal tumor GIST. Journal of Hematology & Oncology 5(1): 21, 2012

Gastrointestinal stromal tumor: involvement in urologic patients and recent therapeutic advances. Urology 60(2): 218-222, 2002

Recent advances in cell biology, diagnosis, and therapy of gastrointestinal stromal tumor (GIST). Cancer Biology and Therapy 3(3): 251-258, 2004

Clinical pathology of gastrointestinal stromal tumor With special reference to change of the cencept of gastrointestinal mesenchymal tumor and the definition and organ specificity of GIST. Stomach & Intestine 36(9): 1113-1127, 2001

Clinical pathology of gastrointestinal stromal tumor (GIST): With special reference to change of the cencept of gastrointestinal mesenchymal tumor (GIMT) and the definition and organ specificity of GIST. Stomach and Intestine 36(9): 1113-1127, 2001

Recent advances in the treatment of gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology 6(3): 115-127, 2014

Recent advances in therapy for gastrointestinal stromal tumors. Current Oncology Reports 9(3): 165-169, 2007

Recent advances in the management of gastrointestinal stromal tumors. Current Oncology Reports 5(4): 288-294, 2003

Recent advances in the management of gastrointestinal stromal tumors. F1000 Medicine Reports 2, 2010

Recent advances in pathology of endometrial stromal tumors. Zhonghua Bing Li Xue Za Zhi 35(12): 752-754, 2007

Gastrointestinal stromal tumors: recent advances in understanding of their biology. Human Pathology 30(10): 1213-1220, 1999

Advances in the treatment of gastrointestinal stromal tumor. Advances in Therapy 26(9): 826-837, 2010